FDA chief: Transparency, commitment key to regaining public trust

10/14/2009 | CNNMoney/Fortune

The FDA is undertaking initiatives to make its decision-making process more transparent as a means to regaining public trust and confidence in the agency, FDA Commissioner Margaret Hamburg said in an interview. The agency also needs to develop a more streamlined regulatory process for drugs and other medical products to include the application of biomarkers and test-animal models, Hamburg said.

View Full Article in:

CNNMoney/Fortune

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD